| | | 20,000+ Fresh Resumes Monthly | |
|
|
| |
Click here or scroll down to respond to this candidate Candidate's Name
9 South Post Lane
Airmont, NY Street Address
Business PHONE NUMBER AVAILABLE . Cell PHONE NUMBER AVAILABLE .
EMAIL AVAILABLE
Summary:
Over 30 years of proven new business and senior management experience for
leading healthcare not-for-profit and communications companies; providing
strategic and tactical leadership for many top selling prescription and
over-the counter brands.
2003
to present Senior Vice President, new business development/client
services
National Minority Quality Forum
(NMQF)/National Health Index (NHI)
Washington, DC.
Primary responsibilities and accomplishments:
. Responsible for generating $2.5 M - $3.5 M annual billings
for not-for-profit NMQF and our for-profit subsidiary,
National Health Index LLC
. Developed client base that includes most major
pharmaceutical companies
. Co-conceived, currently markets and develops annual
National Summit on Health Disparities (2004 - present). The
annual Summit is the only national forum that brings
together congressional leaders, federal executives,
physicians, senior advocacy, managed care and
pharmaceutical industry representatives, as well as other
influential stakeholders, to identify integrated solutions
to health disparities.
> Annual summit revenue (median average) $500 K -
$650K
(ref: http://www.youtube.com/watch?v=qR9M9qvlFVk)
. Introduced and market novel internet-based disease indexes
for the healthcare industry that provide demographic
intelligence about chronic disease prevalence, costs,
outcomes, and associated trends - segmented by
race/ethnicity, age, and gender - by state, by MSA, and by
zip code
(refs: www.afibindex.com/www.hepcindex.com ). The indexes
serve as a data source for developing and implementing
strategic-based marketing, educational, advocacy and policy
initiatives for drug companies.
> Clients include Abbvie, BMS, Genentech, Merck,
Novartis, Pfizer, Roche Diagnostics, and Sanofi
. Developed and market the www.ctengagementnetwork.com (CTEN)
to research-based drug companies. CTEN is a collaborative
of NMQF and the Pharmaceutical Research and Manufacturers
of America (PhRMA). CTEN is a new, innovative resource
designed to deliver a cost-effective solution to improving
diversity in clinical trials. Our recently launched
national 'IM IN' campaign https://www.joinimin.org is
designed to catalyze awareness and recruitment of
minorities into clinical trials.
> Signed three contracts (within 6 months from launch
of CTEN) with pharmaceutical company clients to
support their minority clinical trial recruitment
efforts
2001
to 2003 Vice President, Client Services
Torre Lazur Communications
Parsippany, NJ
Primary responsibilities and accomplishments:
. Provided strategic management services for $3B Paxil
(GSK)advertising account
. Developed competitive plan in anticipation of launch of new
competitive products
1999
to 2001 Partner
MedTier Communications, Inc.
Bardonia, NY
Primary responsibilities and accomplishments:
. Led new business and management responsibilities for
nascent healthcare communication company
. Won three new business accounts: Pharmacia (Xanax XR) -
Projects; Bristol-Myers Squibb (Mature brands group);
InKine Pharmaceuticals (Visocol) - new product launch (Fee
account)
1997 Senior Vice President, Client Services
to 1999 Carrafiello ? Diehl & Associates
Irvington-on-Hudson, NY
Primary responsibilities and accomplishments:
. Led new business and account responsibilities to win and
manage two major accounts: Pharmacia
(NasalCrom /PediaCare ; Novartis Nutritionals (IsoSource
and FiberSource ); and Block Drug Corp. (Atridox ,
Sensodyne ).
1994 Vice President, Client Services
to 1997 Klemtner Advertising
New York, NY
Primary responsibilities and accomplishments:
. Led senior account management responsibilities for the
launch of the
cardiovascular, Aceon (Rhone-Poulenc
Rorer). Pre-launch activities
included creative development through submission of
promotional
materials to DDMAC; pre-launch educational activities;
sales training.
. Provided secondary account management responsibilities for
Immunex oncology (Leukine and Thioplex ).
1988 Vice President, Management Supervisor
to 1994 Lewis and Gace
Fort Lee, NJ.
Primary responsibilities and accomplishments
. Member of new business team that won the following
accounts: Abbott (Teflox ); Syntex (Cardene ) ; and Merck
(Proscar )
. Grew international account (Bristol-Myers Squibb) to over
$1 million in annualized billings
. Named agency of the year (1992)
1985 Account Supervisor
to 1988 Robert A. Becker
New York, NY.
Primary responsibilities and accomplishments:
. Successfully launched the antidepressant Pamelor
(Sandoz/Novartis)
. Directed account management responsibilities for the anti-
psychotic Mellaril
1984 Account Executive
to 1985 William Douglas McAdams
Primary responsibilities and accomplishments:
. Provided account responsibilities for the anti-diabetic,
Diabinese (Pfizer)
and the antibiotic Claforan (Hoechst-Roussel).
1980 Research Scientist
To 1984 Wyeth-Ayerst Laboratories
Pearl River, NY.
Primary responsibilities and accomplishments:
. Awarded a patent for the development of an acellular DTP
vaccine for
pediatric use
. Supervised product development for numerous adult and
pediatric
vaccines; prepared GMP documents for FDA review
Education
Master of Business Administration (with honors)
Pace University
White Plains, NY.
Master of Science in Biology
Millersville University,
Millersville, Pa.
Bachelor of Science in Biology
Millersville University,
Millersville, Pa.
Publications
"What's Next for the Pharmaceutical Industry"
Product Management Today. 7(1); 32-35. 1996
"The Future Role of Rx Advertising"
Pharmaceutical Executive. 9; 42-48. 1993
"Direct-to-Consumer Ads? Drug firms see Pluses, Minuses.
Drug Topics. 129; 60-61.
"Succinate dehydrogenase Metabolism in Rana catesbeiana
Tadpole Liver during Triiodothyronine-induced
Metamorphosis.
Proceedings of the Pennsylvania Academy of Science.
54. 61-62.
1980.
Patent
Enhanced large-scale cultivation of Bordetella pertussis
cells for
vaccine production using lactoglobulin. US Patent No.
4,699,786.
|
